Introduction and background
On 10 May 2018 the Senate referred the provisions of the Criminal Code
and Other Legislation Amendment (Removing Commonwealth Restrictions on
Cannabis) Bill 2018 (the bill) to the Legal and Constitutional Legislation
Committee (the committee) for inquiry and report by 17 August 2018.
The Senate Selection of Bills Committee recommended that the bill be
referred for inquiry for the following reasons:
As the first legislation to propose the removal of
Commonwealth restrictions on cannabis, there is a case to examine: the merits
of legalisation, law enforcement issues, extradition issues, constitutionality,
treaty issues, trade rule issues, Commonwealth-state issues, and budget issues.
Background and purpose of the bill
The bill is a private members bill introduced into the Senate by
Senator David Leyonhjelm.
In his second reading speech, he stated that the bill was informed by the
Adults should be free to make their own choices, as long as
they do not harm others.
Accordingly, this Bill removes offences and civil penalty
provisions in Commonwealth law for dealings with cannabis.
The Explanatory Memorandum outlines that the bill 'would allow any State
or Territory Government to legalise and regulate cannabis'.
It further states that this would address several issues:
The prohibition of cannabis casts otherwise law-abiding
citizens as criminals, increases pressure on the criminal justice system and
props up organised and violent crime.
Legalising cannabis is estimated to reduce annual
Commonwealth law enforcement expenditure by around $100 million and increase
annual GST revenue by around $300 million...
Cannabis use is less harmful than alcohol use and tobacco
Legalising cannabis would improve access to cannabis for
recreational, medicinal, industrial and other purposes. Access for medicinal
purposes is currently hamstrung through excessive regulation.
Provisions of the bill
The bill would amend a number of Commonwealth laws that currently prohibit
and control cannabis, namely the:
Criminal Code Act 1995 (Criminal Code) and Criminal
Code Regulations 2002 (Criminal Code Regulations);
Crimes (Traffic in Narcotic Drugs and Psychotropic Substances)
Act 1990 (Crimes Act);
Defence Force Discipline Act 1982 (Defence Discipline Act);
Narcotic Drugs Act 1967 (Narcotic Drugs Act); and the
Therapeutic Goods Act 1989 (TGA Act).
In his second reading speech, Senator Leyonhjelm provided an outline of how
the bill would amend these Acts. Regarding the Criminal Code Act and
Regulations, he stated that the bill:
...prevents cannabis, including any product obtained from a
cannabis plant, from being defined as a controlled or border controlled drug.
In so doing the Bill excludes dealings with cannabis from the serious drug
offences in the Commonwealth Criminal Code. For completeness, the Bill amends
the Criminal Code Regulations 2002 so that cannabis and
tetrahydrocannabinols (THC) are no longer listed as controlled and border
Regarding the Crimes Act, the Senator commented that the bill would :
...[remove] cannabis and THC from the Act's definition of
narcotic drug, and removes dealings in cannabis and THC from the Act's
definition of dealing in drugs. Together this serves to remove dealings with
cannabis from the Act's offence provisions.
Further to this, the Senator stated that the bill would remove redundant
references in the Defence Discipline Act, while 'maintaining the existing
disciplinary consequences for dealings with other drugs'.
Senator Leyonhjelm noted that the bill would also repeal:
...Chapter 2 of the [Narcotic
Drugs] Act, which establishes medicinal cannabis licences and imposes offences
and civil penalties for dealings with cannabis that are not authorised by such
licences. The Bill also amends Chapter 3 of the Act, which establishes drug
manufacture licences and imposes offences and civil penalty provisions for
dealings with drugs that are not authorised by such licences. Chapter 3 is
amended so these licences and the associated offences and civil penalty
provisions do not apply with respect to dealings with cannabis.
Senator Leyonhjelm stated that the bill would amend the TGA Act, so that:
...the Poisons Standard established by the Act does not apply
in relation to cannabis. This will be consistent with the non-application of
the Poisons Standard to nicotine in tobacco prepared and packed for smoking. It
will also ensure that the Act cannot be used as a vehicle to ban cannabis.
According to Senator Leyonhjelm, the bill would allow states and
territories some discretion in regulating cannabis. If passed, the bill would
start one year following Royal Assent, which he said would allow time for:
...state and territory governments to choose to maintain or
alter their own laws relating to cannabis. They may maintain their bans on
cannabis, with exemptions for medicinal use, if they choose. Alternatively,
they may legislate to allow broader use and to regulate with respect to various
matters such as children and driving.
States and territories
Cannabis is controlled and prohibited by Commonwealth laws, including
the regulation of cannabis for medical use. Within this framework, all jurisdictions
are able to adopt a range of approaches to policing cannabis, including:
decriminalising the possession and use of cannabis for personal use; police
being able to issue a number of 'cautions' for possession before laying a
criminal charge; encouraging attendance at education programs rather than
pressing charges; and/or the ability to refer users found in possession of
cannabis to mandatory intervention programs.
Commonwealth approach to cannabis
The submission made by the Commonwealth Department of Health stated that
the Commonwealth's approach to cannabis treated it as both narcotic and
medicine, including through the National Drug Strategy 2017–2026 (National Drug
Strategy). This approach, they suggested:
...reflects Australia's balanced health and law enforcement
approach to reducing the impact of illicit drug use, tobacco use and the
harmful use of alcohol. Relevantly, all scheduling decisions include
consideration of a standard set of factors, to ensure that public health
objectives are consistently met and the application of public health risk
considerations is consistent within each Schedule.
The National Drug Strategy describes the use, prevalence and potential harms
of cannabis as follows:
Cannabis is a group of substances from the plant cannabis
sativa and is available in three main forms: flowering heads, cannabis resin
(hashish) and cannabis oil. It is usually smoked, either in a hand-rolled cigarette
or through a water-pipe.
In 2016, 10.4% of
Australians over the age of 14 had used cannabis in the last 12 months and
34.8% had used cannabis in their lifetime.
As the most widely used of the illicit drugs in Australia, cannabis carries a
significant burden of disease. The use of cannabis can result in various health
impacts, including mental illness, respiratory illness, and cognitive defects.
In particular, cannabis dependence among young adults is correlated with, and
probably contributes to, mental disorders such as psychosis.
The National Drug Strategy outlines the 'harm minismisation' model that
is central to the Commonwealth's approach to illicit drugs and drug abuse. This
consists of three pillars: demand reduction, supply reduction and harm reduction
(see figure below).
On law enforcement matters, the Strategy includes Crimtrac data
indicating that the police issued 11,809 diversions for cannabis-related
offences in 2014–15.
Use of illicit cannabis in Australia
The National Drug Household Survey 2016 indicated that cannabis is the
most widely used illegal drug in Australia, with 10.4 per cent of respondents
saying they had used it at least once in the past 12 months, well above the
usage rates of other illicit substances. The survey indicated that around 35
per cent of Australians would use cannabis at least once in their lifetime (6.9
The Survey also indicated that cannabis was often used in combination
with other illicit substances, particularly:
...among users of hallucinogens (88%), ecstasy (79%), synthetic
cannabinoid (78%) and meth/amphetamines (74%). However, cannabis users and
people who misused pharmaceuticals were the most likely to only use those
substances in the same 12-month period and not use any other illicit drug,
while users of other psychoactive substances had used at least 1 other
illicit drug, with quite high usage among this group—over half had used
cannabis, ecstasy and hallucinogens.
The survey also noted a general decline in the use of cannabis among the
Australian population between 2001 and 2016, with users being older on average
(34 years in 2016 compared with 29 in 2001).
This decline was especially apparent among younger Australians, when compared
to previous generations:
While there were no
significant declines among 14–19 year olds in recent illicit drug use between
2013 and 2016, use was considerably lower than in 2001—[including that the] use
of cannabis has halved....
Commonwealth laws on medicinal cannabis products
The Commonwealth facilitates access to medicinal products for
appropriate patients for 'medical conditions where there is evidence to support
its use'. This is implemented by the Department of Health, through the
Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC).
The TGA states on its website that:
Medicinal cannabis products are regulated as medicines in
Australia and are therefore subject to legal requirements. Generally, medicines
imported into, supplied in, and exported from Australia must be entered in the
Australian Register of Therapeutic Goods (ARTG), which is administered by the
TGA. Medicinal cannabis products not on the ARTG can be supplied through
alternative pathways until more clinical evidence is gathered through clinical
trials to support its registration. These alternative pathways make reference
to Special Access Scheme (SAS) and Authorised Prescriber (AP).
Regarding the cultivation of cannabis, the TGA states:
On the 30 October 2016, legislation came into effect to allow
legal cultivation, production and manufacturing of medicinal cannabis products
in Australia. The legislative changes forecasted an increase availability of
medicinal cannabis products available to suitable patients. The ODC administers
this scheme and works in collaboration with therapeutic goods legislation and
state and territory legislation. The ODC is responsible for the regulation of
domestic cultivation and harvest, as well as other aspects of manufacture of
medicinal cannabis, under the [Narcotics Drug Act].
The TGA notes that individual consumers cannot apply to obtain approval
to import and access unapproved medicinal cannabis products, but have to go
through an Australian registered doctor with ' appropriate qualifications
and/or expertise for the medical condition requiring treatment' who can make
approvals on a case-by-case basis. Regarding the obligations of doctors wishing
to apply for cannabis products for their patients, the TGA notes the
Gain informed consent from the
patient in relation to the proposed use of the unapproved product. The doctor
and patient, patient's parents or guardian accept responsibility for any
adverse consequence of therapy.
Notify/apply on a patient's behalf
for approval/authorisation to supply these products through the available
Commonwealth access schemes...
requirements are satisfied.
Obtain an import license/ permit
to import the product through the Office of Drug Control. Please note this may
not be applicable if a product is currently being held in Australia.
Monitor patient outcome and report
any suspected adverse drug reactions.
Senate inquiry into personal choice and community impacts of cannabis
On 25 June 2015, the Senate referred an inquiry into personal choice and
community impacts to the Senate Economics References Committee for inquiry and
report by 13 June 2016.
Due to the general election on 2 July 2016, this inquiry lapsed and was
subsequently not re-referred in the 45th Parliament.
The committee tabled an interim report into the sale and use of
marijuana and associated products in May 2016, which recommended that:
...the Australian Government, in conjunction with the states
and territories, undertake an objective assessment of prohibition,
decriminalisation, limited deregulation and legalisation, including a full
cost-benefit analysis, based on the outcomes of these options in other parts of
Financial implications of the bill
The Explanatory Memorandum states that the bill would have a positive
impact on the Commonwealth Budget, improving the fiscal balance of the
Commonwealth Budget by $342 million, as well as lifting its underlying
cash balance by $292 million over the forward estimates.
The Explanatory Memorandum includes a policy costing undertaken by the
Parliamentary Budget Office (PBO) for Senator Leyonhjelm, which was completed
on 21 September 2016. This costing summarises the financial aspects of the bill
The proposal would legalise all marijuana/cannabis/hemp use
by adults, as well as possession, cultivation, processing, transport, trade,
import and export. No excise would be imposed on marijuana.
This proposal would also reduce the budgets of relevant
federal agencies including the Australian Federal Police (AFP), Australian
Criminal Intelligence Commission (ACIC), and the Australian Border Force (ABF)
by the level of funding directly associated with marijuana law enforcement.
An estimate of the effect of this proposal on total marijuana
usage was also requested.
The PBO provided a comprehensive list of underlying assumptions used for
the modelling of these costings, but advised this 'costing is considered to be
of low reliability', as:
...[there] is uncertainty regarding the price and quantity of
marijuana currently consumed, and the price and quantity of marijuana that
would be consumed in a newly legalised market. It is also difficult to
separately identify marijuana law enforcement activities, as these are often
integrated within broader law enforcement activities.
Compatibility with human rights
The Explanatory Memorandum states that the bill is compatible with the
human rights and freedoms recognised or declared in the international instruments
listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.
The Explanatory Memorandum sets out some of the human rights implications
implicit in the bill:
Adults should be free to make their own choices as long as
they do not harm others.
The Bill protects the right of self-determination, the right
to freely pursue one's economic, social and cultural development, and the right
to freely dispose of one's natural wealth and resources. These rights are
recognised in Article 1 of the International Covenant on Economic, Social and
Cultural Rights and Article 1 of the International Covenant on Civil and
Senate Scrutiny of Bills Committee
The Senate's Scrutiny of Bills Committee (Scrutiny Committee) commented
on the bill's reversal of the legal burden of proof, noting that:
The bill seeks to amend the Defence Force Discipline Act
1982 (the Act) to insert five offences relating to defence members or
defence civilians dealing in, possessing or administering prohibited drugs. It
also seeks to provide that it would be a defence to each of these offences if
the person proves that he or she had lawful authority for engaging in the
relevant conduct. The defendant would bear a legal burden of proof in relation
to each of these defences, ensuring that the defendant would need to prove, on
the balance of probabilities, that he or she had lawful authority for engaging
in the relevant conduct. The proposed
offences carry maximum penalties ranging from a fine of three penalty units to
imprisonment for 10 years. The proposed section largely mirrors existing
section 59 in the Act, with the exception that provisions setting out specific
penalties where the conduct involves cannabis have been removed.
At common law, it is ordinarily the duty of the prosecution
to prove all elements of an offence. This is an important aspect of the right
to be presumed innocent until proven guilty. Provisions that reverse the burden
of proof and require a defendant to disprove one or more elements of an offence,
interfere with this common law right.
The Scrutiny Committee further argued:
As the reversal of the burden of proof undermines the right
to be presumed innocent until proven guilty, the committee expects there to be
a full justification in the explanatory memorandum each time the burden is
reversed, with the rights of people affected being the paramount consideration.
In this instance, the explanatory memorandum does not address the fact that
proposed section 59 seeks to reverse the legal burden of proof in relation to
the lawful authority defences set out in proposed subsections 59(2), (4), (5A),
(6A) and (8).
After noting these concerns, the Scrutiny Committee left the decision
about the appropriateness of the bill's reversal of the legal burden of proof
to the Senate as a whole.
Conduct of the inquiry
Details of the inquiry were advertised on the committee's website,
including a call for submissions to be received by 15 June 2017. The committee
also wrote directly to a number of individuals and organisations inviting them
to make submissions.
The committee received 36 submissions, all available on the committee's
website. A list of all submissions received is at appendix 1 of this report.
The committee held a public hearing in Canberra on 17 August 2018. A
full list of all witnesses who gave evidence to the committee at this hearing
is at appendix 2 of this report.
Structure of this report
This report consists of two chapters:
This chapter provides a brief background and overview to the
bill, as well as the administrative details of the inquiry; and
Chapter 2 discusses the evidence received by the committee supporting
and opposing the bill, and sets out the committee's views and recommendation.
The committee thanks all organisations and individuals that made
submissions, as well as those that appeared at the public hearing.
Navigation: Previous Page | Contents | Next Page